RxDoctor Payments Data

Stephen Simpson, MD

Cardiovascular Disease · Lafayette, LANPI 1235128026

Payments from drug & device makers

$1,331in general payments, 2019–2025

Across 24 payments — averaging $55.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$934
  • Abbott$118
  • Welch Allyn$61
  • Baxter Healthcare$61
  • Medtronic$36
  • Amgen$32
  • plus $87 from 5 others

What the payments were for

  • Food & beverage$1,20991%
  • Other$1229%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,331 in reported general payments places this provider in the 30th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$720,108
Medicare patients
1,800
Services billed
7,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,137$888,904
XareltoRivaroxaban353$246,210
EntrestoSacubitril/Valsartan259$219,986
Repatha SureclickEvolocumab197$120,530
MultaqDronedarone Hcl72$68,526
Dabigatran EtexilateDabigatran Etexilate Mesylate100$20,512
JardianceEmpagliflozin29$20,424
Ranolazine ErRanolazine331$20,137
Metoprolol Succinate1,764$16,226
Diltiazem 24hr Er (Cd)Diltiazem Hcl580$12,229
LivaloPitavastatin Calcium34$10,595
NexletolBempedoic Acid20$8,721
Bisoprolol Fumarate393$7,025
ClopidogrelClopidogrel Bisulfate704$6,637
Rosuvastatin Calcium619$6,221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Esperion Therapeutics, Inc.Nexletol$12$8,72120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →